Omega Therapeutics Touts Encouraging Preclinical Data In Liver Cancer Animal Models

Omega Therapeutics Inc OMGA has presented new preclinical data on its lead product candidate, OTX-2002, in multiple models of hepatocellular carcinoma.
In non-human primates, treatment with OTX-2002 resulted in a durable reduction of MYC mRNA levels in the liver consistent with previous in vitro and in vivo studies.
OTX-2002 treatment decreased c-Myc mRNA, protein levels, and cell viability in multiple HCC cell lines while sparing normal cells.
Related: Omega Therapeutics Submits IND For Liver Cancer Candidate.
OTX-2002 significantly reduced tumor growth in HCC xenografts models.
OTX-2002 treatment is associated with decreased expression of the immune checkpoint factor PD-L1 in HCC cells, suggesting a potential role for combination therapy with immune checkpoint inhibitors.
Combining OTX-2002 with the existing standard of care therapies for HCC resulted in further reduction of cell viability and tumor burden in both in vitro and in vivo HCC models.
Price Action: OMGA shares are down 1.41% at $4.20 during the market session on the last check Thursday.